Latest Conference Articles

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

Catch up on coverage from the first day of the 2025 European Academy of Dermatology and Venereology Congress held in Paris, France.

At the 2025 EADV Congress in Paris, phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.

A new study at EADV 2025 links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.

According to a poster at the 2025 EADV Congress, barzolvolimab achieved comparable improvements in weekly Urticaria Activity Scores across immunoglobulin E (lgE) subgroups.

Sanofi's brivekimig shows promising phase 2a results for hidradenitis suppurativa (HS), offering hope for effective treatment options at EADV Congress 2025.

At EADV 2025, UCB presented new long-term data demonstrating bimekizumab’s durable efficacy and a consistent safety profile over extended treatment.

STOP-HS1 and STOP-HS2 phase 3 trials showed nearly 60% of patients achieving HiSCR50 by week 24, according to a presentation at EADV 2025.

By blocking 2 key inflammation signals, research presented at EADV found bimekizumab may help keep both skin and joints healthier over time.

At EADV, research showed benefits of zasocitinib on quality of life were observed as early as week 4 and sustained through week 12.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of September.

Katrina Lee, MD, discussed innovative strategies and challenges in managing HS at the Dermatology Innovation Symposium, emphasizing early intervention and comprehensive care.

Discover the latest in regenerative aesthetics and body contouring at DERM 2025, featuring insights from Suneel Chilukuri, MD, on skin care trends and biohacking.

Members of Elevate-Derm Alliance and the SkinSync podcast discuss the inspiration behind the podcast and how it best serves dermatology clinicians.

Lisa Swanson, MD, FAAD, shares innovative insights on pediatric dermatology, emphasizing effective treatments and communication strategies for young patients at DERM 2025.

April Martinez-Dulay, MSN, APRN, FNP-BC, shares insights on diagnosing and treating types of dermatitis at DERM 2025, emphasizing innovative approaches and patient care strategies.

Clinicians at the SDPA Annual Summer Dermatology Conference explore innovative treatments, diagnostic strategies, and patient-centered care in dermatology.

James Song, MD, FAAD, reveals insights on abrocitinib's safety in atopic dermatitis, highlighting lower conjunctivitis rates compared to dupilumab at DERM 2025.

At DERM 2025, David Cotter, MD, PhD, shared how GEP testing revolutionizes skin cancer management and enhances patient care at the forefront of dermatology innovation.

Explore key insights and highlights from SPD 2025, focusing on pediatric dermatology advancements, innovative treatments, and expert reflections from the conference.

Unlock exclusive insights from Elevate-Derm Summer 2025 and get expert pearls, emerging data, and clinical strategies at your fingertips.

Virginia Sybert, MD, emphasized the importance of using genetic testing judiciously in dermatologic care.

According to a new poster, patients with chronic spontaneous urticaria seek better relief options, highlighting significant impacts on quality of life and mental well-being globally.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of August.

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections

Coates addresses social determinants of health in pediatric dermatology, emphasizing their impact on treatment and patient outcomes.